Academic Journal
Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story?
| العنوان: | Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story? |
|---|---|
| المؤلفون: | Cosgrove, Casey M., Backes, Floor J., O'Malley, David, Bixel, Kristin L., Suarez, Adrian A., Fowler, Jeffrey M., Copeland, Larry J., Goodfellow, Paul J., Cohn, David E. |
| المصدر: | The Oncologist ; volume 26, issue 12, page 1044-1051 ; ISSN 1083-7159 1549-490X |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2021 |
| الوصف: | Background Endometrial cancer (EC) is the most common gynecologic cancer in the U.S. The objective of this cohort study was to characterize the clinical and pathologic features that are associated with endometrial cancer–specific death for women cared for at a single National Cancer Institute–designated comprehensive cancer center. Patients, Materials, and Methods This is a retrospective cohort from 2014 to 2017 including all women who had a hysterectomy for EC. Charts were reviewed for clinical and pathologic data, focusing on survival outcomes. Results Seven hundred seventy-one patients with EC underwent hysterectomy with 760 informative for outcomes. Seventy-six (10%) deaths were related to their EC; 62 women died from recurrent EC. Nonendometrioid histology and advanced stage were predictors of recurrence and EC death. Among patients with endometrioid ECs, mismatch repair status was significantly associated with EC-specific survival (relative risk = 4.8; 95% confidence interval, 2.3–10.3; p < .0001). Most patients with EC who recurred died of their disease 62/83 (74.7%). Nearly half of the patients that recurred (27/62) had no additional therapy at the time of recurrence. Overall survival was significantly longer for those women who had additional treatment at the time of recurrence; however, the improvement in overall survival with therapy at recurrence was largely attributable to effects in those women who were adjuvant therapy naïve. Conclusion Although there is benefit of treatment at the time of recurrence for treatment-naïve women; only approximately half of patients were able to receive therapy. There is an urgent need for continued efforts for more effective EC therapy in both the front-line and recurrent setting as well as early identification of cancer diagnosis and recurrence. Implications for Practice Approximately 10% of patients died of their endometrial cancer. Most deaths were from recurrent disease; however, almost 20% of endometrial cancer deaths were within 120 days of ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1002/onco.13934 |
| الاتاحة: | https://doi.org/10.1002/onco.13934 https://onlinelibrary.wiley.com/doi/pdf/10.1002/onco.13934 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/onco.13934 https://academic.oup.com/oncolo/article-pdf/26/12/1044/42242496/oncolo_26_12_1044.pdf |
| Rights: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| رقم الانضمام: | edsbas.D0F3ACC4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/onco.13934 |
|---|